Cargando…
Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis
Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer. Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most important dose‐limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the ass...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579387/ https://www.ncbi.nlm.nih.gov/pubmed/35892315 http://dx.doi.org/10.1111/cts.13370 |
_version_ | 1784812170147528704 |
---|---|
author | Guijosa, Alberto Freyria, Ana Espinosa‐Fernandez, Jose Rodrigo Estrada‐Mena, Francisco J. Armenta‐Quiroga, Ana Sofía Ortega‐Treviño, Maria Fernanda Catalán, Rodrigo Antonio‐Aguirre, Bani Villarreal‐Garza, Cynthia Perez‐Ortiz, Andric C. |
author_facet | Guijosa, Alberto Freyria, Ana Espinosa‐Fernandez, Jose Rodrigo Estrada‐Mena, Francisco J. Armenta‐Quiroga, Ana Sofía Ortega‐Treviño, Maria Fernanda Catalán, Rodrigo Antonio‐Aguirre, Bani Villarreal‐Garza, Cynthia Perez‐Ortiz, Andric C. |
author_sort | Guijosa, Alberto |
collection | PubMed |
description | Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer. Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most important dose‐limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the association remain unclear. For this reason, we systematically reviewed observational studies of TIPN pharmacogenetic markers in breast cancer treatment. We conducted a systematic search of terms alluding to breast cancer, genetic markers, taxanes, and neurotoxicity in Ovid, ProQuest, PubMed, Scopus, Virtual Health, and Web of Science. We assessed the quality of evidence and bias profile. We extracted relevant variables and effect measures. Whenever possible, we performed random‐effects gene meta‐analyses and examined interstudy heterogeneity with meta‐regression models and subgroup analyses. This study follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidance. A total of 42 studies with 19,431 participants were included. These evaluated 262 single‐nucleotide polymorphisms (SNPs) across 121 genes. We conducted meta‐analyses on 23 genes with 60 SNPs (19 studies and 6246 participants). Thirteen individual SNPs (ABCB1‐rs2032582, ABCB1‐rs3213619, BCL6/‐rs1903216, /CAND1‐rs17781082, CYP1B1‐rs1056836, CYP2C8‐rs10509681, CYP2C8‐rs11572080, EPHA5‐rs7349683, EPHA6‐rs301927, FZD3‐rs7001034, GSTP1‐rs1138272, TUBB2A‐rs9501929, and XKR4‐rs4737264) and the overall SNPs' effect in four genes (CYP3A4, EphA5, GSTP1, and SLCO1B1) were statistically significantly associated with TIPN through meta‐analysis. In conclusion, through systematic review and meta‐analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making. |
format | Online Article Text |
id | pubmed-9579387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95793872022-10-19 Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis Guijosa, Alberto Freyria, Ana Espinosa‐Fernandez, Jose Rodrigo Estrada‐Mena, Francisco J. Armenta‐Quiroga, Ana Sofía Ortega‐Treviño, Maria Fernanda Catalán, Rodrigo Antonio‐Aguirre, Bani Villarreal‐Garza, Cynthia Perez‐Ortiz, Andric C. Clin Transl Sci Research Taxane‐based chemotherapy regimens are used as first‐line treatment for breast cancer. Neurotoxicity, mainly taxane‐induced peripheral neuropathy (TIPN), remains the most important dose‐limiting adverse event. Multiple genes may be associated with TIPN; however, the strength and direction of the association remain unclear. For this reason, we systematically reviewed observational studies of TIPN pharmacogenetic markers in breast cancer treatment. We conducted a systematic search of terms alluding to breast cancer, genetic markers, taxanes, and neurotoxicity in Ovid, ProQuest, PubMed, Scopus, Virtual Health, and Web of Science. We assessed the quality of evidence and bias profile. We extracted relevant variables and effect measures. Whenever possible, we performed random‐effects gene meta‐analyses and examined interstudy heterogeneity with meta‐regression models and subgroup analyses. This study follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and STrengthening the REporting of Genetic Association Studies (STREGA) reporting guidance. A total of 42 studies with 19,431 participants were included. These evaluated 262 single‐nucleotide polymorphisms (SNPs) across 121 genes. We conducted meta‐analyses on 23 genes with 60 SNPs (19 studies and 6246 participants). Thirteen individual SNPs (ABCB1‐rs2032582, ABCB1‐rs3213619, BCL6/‐rs1903216, /CAND1‐rs17781082, CYP1B1‐rs1056836, CYP2C8‐rs10509681, CYP2C8‐rs11572080, EPHA5‐rs7349683, EPHA6‐rs301927, FZD3‐rs7001034, GSTP1‐rs1138272, TUBB2A‐rs9501929, and XKR4‐rs4737264) and the overall SNPs' effect in four genes (CYP3A4, EphA5, GSTP1, and SLCO1B1) were statistically significantly associated with TIPN through meta‐analysis. In conclusion, through systematic review and meta‐analysis, we found that polymorphisms, and particularly 13 SNPs, are associated with TIPN, suggesting that genetics does play a role in interindividual predisposition. Further studies could potentially use these findings to develop individual risk profiles and guide decision making. John Wiley and Sons Inc. 2022-08-17 2022-10 /pmc/articles/PMC9579387/ /pubmed/35892315 http://dx.doi.org/10.1111/cts.13370 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Guijosa, Alberto Freyria, Ana Espinosa‐Fernandez, Jose Rodrigo Estrada‐Mena, Francisco J. Armenta‐Quiroga, Ana Sofía Ortega‐Treviño, Maria Fernanda Catalán, Rodrigo Antonio‐Aguirre, Bani Villarreal‐Garza, Cynthia Perez‐Ortiz, Andric C. Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis |
title | Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis |
title_full | Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis |
title_fullStr | Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis |
title_full_unstemmed | Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis |
title_short | Pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: Systematic review and meta‐analysis |
title_sort | pharmacogenetics of taxane‐induced neurotoxicity in breast cancer: systematic review and meta‐analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579387/ https://www.ncbi.nlm.nih.gov/pubmed/35892315 http://dx.doi.org/10.1111/cts.13370 |
work_keys_str_mv | AT guijosaalberto pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT freyriaana pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT espinosafernandezjoserodrigo pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT estradamenafranciscoj pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT armentaquirogaanasofia pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT ortegatrevinomariafernanda pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT catalanrodrigo pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT antonioaguirrebani pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT villarrealgarzacynthia pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis AT perezortizandricc pharmacogeneticsoftaxaneinducedneurotoxicityinbreastcancersystematicreviewandmetaanalysis |